PCM
APGE

Prelude Capital Management’s Apogee Therapeutics APGE Stock Holding History

Prelude Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.78M Buy
58,590
+52,590
+877% +$4.74M 0.57% 26
2026
Q1 		$505K Buy
+6,000
New +$436K 0.04% 505
2025
Q4 		– Sell
-26,241
Closed -$1.04M – 1284
2025
Q3 		$1.04M Buy
+26,241
New +$1M 0.08% 301

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Prelude Capital Management's APGE Position: Q2 2026 in Review

Prelude Capital Management increased its Apogee Therapeutics (APGE) stake by 877% in Q2 2026, buying an estimated $4.74M and bringing the position to 58,590 shares worth $7.78M. The position accounts for 0.57% of the portfolio, ranked #26.

Prelude Capital Management first reported a position in APGE in Q3 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Prelude Capital Management held 58,590 shares of Apogee Therapeutics worth $7.78M as of Q2 2026.
  • Prelude Capital Management bought 52,590 Apogee Therapeutics shares in Q2 2026, an estimated $4.74M.
  • Apogee Therapeutics made up 0.57% of Prelude Capital Management's portfolio in Q2 2026, its #26 holding.
  • Prelude Capital Management first reported a position in Apogee Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.